Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Iconovo ABOSTO:ICO -9.37%34 Debt-to-EBITDA is -0.24 as of Mar. 2026. GuruFocus rates OSTO:ICO with a GF Score™ of 34/100 and a GF Value™ of kr0.27 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 467 Medical Devices & Instruments companies, Iconovo AB ranks worse than 214132.55% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Iconovo AB's Debt-to-EBITDA or its related term are showing as below:
OSTO:ICO'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.28 Med: -0.26 Max: 0.49
Current: -0.19
During the past 10 years, the highest Debt-to-EBITDA Ratio of Iconovo AB was 0.49. The lowest was -0.28. And the median was -0.26.
OSTO:ICO's Debt-to-EBITDA is ranked worse than 100% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 1.57
vs OSTO:ICO: -0.19
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Iconovo AB Debt-to-EBITDA Related Terms
Iconovo AB Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Iconovo AB's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ICO vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Iconovo AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Iconovo AB Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Iconovo AB's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Iconovo AB's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Iconovo AB (OSTO:ICO) has a Debt-to-EBITDA of -0.24 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Iconovo AB. According to the industry distribution chart, Iconovo AB ranks #999999 out of 467 companies in the Medical Devices & Instruments industry.
Is Iconovo AB's Debt-to-EBITDA too high?
Iconovo AB's current Debt-to-EBITDA is -0.24. Based on the distribution chart, Iconovo AB ranks #999999 out of 467 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Iconovo AB has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Iconovo AB's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Iconovo AB ranks #999999 out of 467 companies for Debt-to-EBITDA. This places Iconovo AB in the lower half of its industry. The industry median Debt-to-EBITDA is 1.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.57, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Iconovo AB. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Iconovo AB's current Debt-to-EBITDA is -0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iconovo AB stock overvalued right now?
Based on GuruFocus' analysis, Iconovo AB (OSTO:ICO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.27, compared to a current price of kr0.94 — trading 247.4% above its estimated fair value. The current Debt-to-EBITDA is -0.24. Iconovo AB's overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Iconovo AB (OSTO:ICO), the current Debt-to-EBITDA is -0.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Iconovo AB (OSTO:ICO) Overvalued in 2026?
Based on GuruFocus' analysis, Iconovo AB stock appears to be overvalued.
The current stock price of kr0.94 is trading 247.4% above its estimated GF Value™ of kr0.27.
GuruFocus considers Iconovo AB to be Significantly Overvalued.
Key valuation signals for OSTO:ICO:
Debt-to-EBITDA: -0.24
GF Value™: kr0.27 vs. price of kr0.94 (247.4% above fair value)
No single metric tells the full story. See the OSTO:ICO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iconovo AB develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The project is a generic version of the asthma and COPD product Symbicort.
34GF Score
Get the complete analysis for OSTO:ICO
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ICO has been successfully added to your 
